Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012739 (
disseminated intravascular coagulation
)
8,673
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Peripheral blood lymphocytes from 32 patients with malignant melanoma were tested for cell-mediated cytotoxicity (CMC) against cultured autologous melanoma cells. Effector cells were prepared from venous blood by
defibrination
, gel sedimentation, nylon column filtration, and lysis of remaining erythrocytes with NH4Cl.
Melanoma
cells prelabelled with [3H])proline were used as target cells in a 40-h assay and CMC was evaluated against standards obtained with blood lymphocytes from the least reactive normal donor. Reproducible autologous CMC was detected in 18 of 32 patients in a series of 367 total tests. CMC correlated with tumor volume (5-500 cm3) but not with tumor stage or DNCB reactivity. Preliminary results indicated that autologous CMC was not affected by treatment with DTIC, dexamethasone, intralesional BCG, radiation therapy, or partial surgical excision. Lack of consistent CMC in 14 patients could not be attributed to a measurable decrease in general immune capacity or to increased resistance of the patients' melanoma cells to CMC in general. Fibroblasts were more resistant to CMC than melanoma cells, and therefore of questionable value for defining specificity in direct tests.
...
PMID:Cell-mediated cytotoxicity for cultured autologous melanoma cells. 47 90
Disseminated intravascular coagulation
is a complex and potentially lethal complication of malignancy, in which the fundamental abnormality is excessive activation of the coagulation system. It is a rare complication of melanoma which can be difficult to diagnose in some circumstances, leading to delay in treatment. Herein, we describe the first case of
disseminated intravascular coagulation
occurring in BRAF and NRAS-mutant metastatic melanoma, and systematically review the literature regarding
disseminated intravascular coagulation
in melanoma. This review summarizes the reported cases of
disseminated intravascular coagulation
in melanoma and those secondary to the novel treatment of melanoma, and explores the pathophysiology of
disseminated intravascular coagulation
in melanoma, highlighting the key role of expression of markers of coagulation and fibrinolysis in
disseminated intravascular coagulation
, as well as more widely in melanoma. Current limitations in the literature are also identified and discussed, particularly with respect to improving the management of this lethal complication.
Disseminated intravascular coagulation
is a rare complication of melanoma that typically portends poor prognosis.
Melanoma
Res 2019 10
PMID:Disseminated intravascular coagulation and melanoma: a novel case occurring in metastatic melanoma with BRAF and NRAS mutations and systematic review. 3109 38